Quantum BioPharma Ltd C.QNTM

I see the website is updated

[DavidRosenberg]

https://fsdpharma.com/about-us/

FSD Pharma Growth Strategy

• Pursue further acquisition targets or potential investments that are unique and align with our mission of Total Brain Health
• Begin the process of advancing clinical trials for its compound Lucid-21-302, for the novel treatment of progressive MS (Multiple Sclerosis)
• Begin the process of advancing clinical trials for the treatment of depression, anxiety and psychiatric disorders through its psychedelic molecule Lucid-201
• Assess the best path forward for the advancement of FSD-201
• Complete the sale of our Cobourg property to increase cash in a non-dilutive method

Lucid Acquisition

• • • FSD Pharma acquired Lucid in September 2021
    • Two pre-clinical lead drug candidates aimed to treat neurodegenerative diseases and neuropsychiatric disorders

    oLUCID-21-302 – target treatment: Multiple Sclerosis

    oLUCID-201 – target treatment: depression & anxiety

    • New Chemical Entities (NCEs) licensed from UHN (largest healthcare research organization in NA) and uniquely paired with psychedelics formulations to improve patient outcomes
    • Large addressable markets: $23 Billion multiple sclerosis market and growing $225 Billion mental health market

FSD-201: Ultra Micro-PEA Compound

• Proprietary ultra micro-PEA formulation enhances the anti-inflammatory properties of PEA, a fatty acid amide currently used as a dietary supplement, by increasing its bioavailability and efficacy- making it suitable to treat a range of inflammatory conditions
• Holds exclusive worldwide licensing rights (except Italy & Spain) to ultra micro-PEA for all conditions in all regulatory categories
• Strong IP portfolio covering ultra-micronized composition of matter and use (2029-34 U.S. expiration)

Lead candidate (FSD 201- 600mg ultra micro-PEA)

Successfully completed Phase 1 first-in-human safety and tolerability trial. No serious adverse effects discovered

Toxicology trials have been completed and the results are being compiled

• Potential Target indications for Phase 2 trials currently being analyzed

Opioid replacement and/or sparing agent

Growing Market Opportunity in Psychedelics

• Growing body of research that suggests Psychedelics have the potential to treat a variety of neuropsychiatric disorders such as PTSD, depression, specifically complex TRD and MDD, and anxiety

FDA approval of Johnson & Johnson’s SPRAVATO (esketamine) for treatment-resistant depression

Meaningful MAPS Ph2 clinical data on MDMA-assisted psychotherapy for PTSD treatment

Expanding pipeline of psychedelic-based therapies

• $225B annual spend for mental health in the U.S.

Comparable Companies

as of September 27, 2021

[Mil_Man54]

And as we can see Rosenberg is posting more PR BS....this is not and never will be a good or reliable source of information for any investor.....it will be a touch point to get a vague idea what they're up to but a much deeper dive is require outside of the PR hype.....but Rosenberg won't tell you that....he'll want you to take FSD at face value and believe everything they say

[DavidRosenberg]

Im not a pumper im a shareholder sharing all types of news or content whenever it comes out... I only have one account It's not PR BS it's news and updates from the company this is the stockmarket my friend pressence needs to be known The HUGE Big reset is happening before your eyes

[Mil_Man54]

I've told Rosenberg before  you can be both a shareholder and a pumper......and yes....it's PR BS that means very little to an actual investor.......and I suggest Rosenberg replace the word "reset" with "scheme"......that would be more to the point......wouldn't you agree my fellow longs.....